AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12374436 — intervention group
Group type: COMPARATOR
Intervention: Sentence unscrambling task (neutral, emotional sentences)
Number of subjects: 0
Study 9931535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment for 3 days
Number of subjects: 28
Study 9931535 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 3 days
Number of subjects: 28
Study 7574816 — intervention group
Group type: COMPARATOR
Intervention: Granisetron monotherapy (40 micrograms/kg)
Number of subjects: 122
Study 7574816 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus steroids (500 mg of methylprednisolone succinate or 8 mg of dexamethasone phosphate prior to granisetron)
Number of subjects: 122
Study 7574816 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus steroids
Number of subjects: 122
Study 7574816 — intervention group
Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 122
Study 2407208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 46
Study 2407208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 224831 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment plus drugs
Number of subjects: 10
Study 224831 — intervention group
Group type: COMPARATOR
Intervention: Drugs alone
Number of subjects: 10
Study 31805462 — intervention group
Group type: EXPERIMENTAL
Intervention: Short story about two foresters solving a resource dilemma
Number of subjects: 132
Study 31805462 — intervention group
Group type: COMPARATOR
Intervention: Control condition: Short informative story on urban gardening
Number of subjects: 132
Study 31056202 — intervention group
Group type: EXPERIMENTAL
Intervention: MEAL Plan
Number of subjects: 38
Study 31056202 — intervention group
Group type: COMPARATOR
Intervention: Parent Education
Number of subjects: 38
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting quadruple therapy
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction of ethambutol
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ciprofloxacin
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Average treatment duration
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical reaction occurrence
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Median delay to onset of paradoxical reaction
Number of subjects: 501
Study 27810522 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for paradoxical reaction
Number of subjects: 501
Study 26290749 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (n = 30)
Number of subjects: 60
Study 26290749 — intervention group
Group type: COMPARATOR
Intervention: Education of patient associated with an active member of the family (n = 30)
Number of subjects: 60
Study 23986910 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month home-based rehabilitation program
Number of subjects: 81
Study 23986910 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 81
Study 20503074 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP with controlled heated breathing tube humidifier (cHH)
Number of subjects: 44
Study 19448527 — intervention group
Group type: EXPERIMENTAL
Intervention: Late diagnosis of HIV infection in truck drivers
Number of subjects: 0
Study 16459223 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 mg daily) and Vitamin C (750 mg daily)
Number of subjects: 30
Study 16459223 — intervention group
Group type: COMPARATOR
Intervention: No vitamin supplementation (control group)
Number of subjects: 30
Study 16459223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (vitamin and non-vitamin)
Number of subjects: 30
Study 15225192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg/day (E + D group, n = 140)
Number of subjects: 279
Study 15225192 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 5 mg/day (E + P group, n = 139)
Number of subjects: 279
Study 15225192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (E + D and E + P)
Number of subjects: 279
Study 11679932 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel plus placebo
Number of subjects: 300
Study 11679932 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus placebo
Number of subjects: 300
Study 11679932 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and praziquantel
Number of subjects: 300
Study 11679932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 10223131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin group
Number of subjects: 44
Study 10223131 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 7838444 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-IBZM SPECT
Number of subjects: 22
Study 7838444 — intervention group
Group type: COMPARATOR
Intervention: 11C-raclopride PET
Number of subjects: 22
Study 3045435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR-4
Number of subjects: 23
Study 3045435 — intervention group
Group type: COMPARATOR
Intervention: Standard Sinemet
Number of subjects: 23
Study 31974825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (air-nitrogen-carbon dioxide mixture with decreased oxygen content) for 90 min
Number of subjects: 9
Study 31974825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 9
Study 28941936 — intervention group
Group type: EXPERIMENTAL
Intervention: ProBalance rehabilitation programme (12 weeks, 90-min sessions, 2 days per week)
Number of subjects: 52
Study 28941936 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (maintained usual activities)
Number of subjects: 52
Study 26885407 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice group (completed six 30-minute practice sessions of three lab-based inhibition tasks)
Number of subjects: 48
Study 26885407 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 48
Study 26885407 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice group
Number of subjects: 48
Study 26205910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention using supplements to increase the intake of EPA and DHA for 12 months
Number of subjects: 204
Study 26205910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention using supplements to increase the intake of EPA and DHA
Number of subjects: 204
Study 23527521 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 88
Study 23527521 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 88
Study 21921571 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 33 μg/kg/day
Number of subjects: 124
Study 21921571 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 67 μg/kg/day
Number of subjects: 124
Study 21921571 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 124
Study 17931758 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (radiochemotherapy)
Number of subjects: 128
Study 17931758 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment (surgery and postoperative radiation)
Number of subjects: 128
Study 17931758 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 128
Study 17931758 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant treatment
Number of subjects: 128
Study 16376314 — intervention group
Group type: EXPERIMENTAL
Intervention: Modal triangle
Number of subjects: 26
Study 16376314 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodal triangle
Number of subjects: 26
Study 16376314 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure with outlined inducers
Number of subjects: 26
Study 16376314 — intervention group
Group type: COMPARATOR
Intervention: No-triangle figure
Number of subjects: 26
Study 12364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum (PP) during laparoscopic GBP
Number of subjects: 30
Study 12364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PP and Reverse Trendelenburg (RT) during laparoscopic GBP
Number of subjects: 30
Study 12364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential compression devices during PP and RT in laparoscopic GBP
Number of subjects: 30
Study 12364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg (RT) during open GBP
Number of subjects: 30
Study 12364988 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential compression devices during RT in open GBP
Number of subjects: 30
Study 10666558 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 80
Study 10666558 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mg of midazolam
Number of subjects: 80
Study 10666558 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of scopolamine
Number of subjects: 80
Study 10666558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8879892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms twice daily
Number of subjects: 304
Study 8879892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 micrograms twice daily
Number of subjects: 304
Study 8879892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 micrograms twice daily
Number of subjects: 304
Study 8879892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 8879892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100, 250, and 500 micrograms)
Number of subjects: 304
Study 1947729 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (HDC)
Number of subjects: 12
Study 1947729 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 12
Study 6344899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (Nuelin SA) 350 mg daily
Number of subjects: 19
Study 6344899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (Nuelin SA) 700 mg daily
Number of subjects: 19
Study 6344899 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol alone
Number of subjects: 19
Study 31243588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 90
Study 31243588 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (steroid)
Number of subjects: 90
Study 31243588 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide plus tenoxicam (steroid plus tenoxicam)
Number of subjects: 90
Study 31243588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 29609103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control training (two-week, six-session program)
Number of subjects: 52
Study 29609103 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 52
Study 27461426 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (2.5-10 mg twice daily)
Number of subjects: 321
Study 27461426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 24275900 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidifiers (HH)
Number of subjects: 247
Study 24275900 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchangers (HME)
Number of subjects: 247
Study 23050440 — intervention group
Group type: EXPERIMENTAL
Intervention: VA supplementation with 600 microg/d retinyl acetate
Number of subjects: 115
Study 23050440 — intervention group
Group type: EXPERIMENTAL
Intervention: VA supplementation with 400 microg/d retinyl acetate
Number of subjects: 115
Study 23050440 — intervention group
Group type: EXPERIMENTAL
Intervention: VA supplementation with 200 microg/d retinyl acetate
Number of subjects: 115
Study 23050440 — intervention group
Group type: COMPARATOR
Intervention: Control group with 0 microg/d retinyl acetate
Number of subjects: 115
Study 20050759 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 68
Study 20050759 — intervention group
Group type: COMPARATOR
Intervention: Infliximab (for Group III)
Number of subjects: 68
Study 18227782 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducational treatment
Number of subjects: 0
Study 18227782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 0
Study 18227782 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy
Number of subjects: 0
Study 18227782 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial control condition
Number of subjects: 0
Study 16002035 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10, 20, or 30 mg)
Number of subjects: 8
Study 16002035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11591884 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (W; 1.2 g/kg/day)
Number of subjects: 36
Study 11591884 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein and creatine monohydrate (WC; 0.1 g/kg/day)
Number of subjects: 36
Study 11591884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P; 1.2 g/kg/day maltodextrin)
Number of subjects: 36
Study 9849446 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐HPR (fenretinide)
Number of subjects: 28
Study 9849446 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 28
Study 8022293 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted form of the Peabody Picture Vocabulary Test-Revised
Number of subjects: 25
Study 8022293 — intervention group
Group type: COMPARATOR
Intervention: Standard form of the Peabody Picture Vocabulary Test-Revised
Number of subjects: 25
Study 2649319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied twice a day
Number of subjects: 348
Study 2649319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied once a day
Number of subjects: 348
Study 19531879 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training (PrT)
Number of subjects: 108
Study 19531879 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 108
Study 19531879 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 108
Study 365391 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 24
Study 365391 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30506679 — intervention group
Group type: EXPERIMENTAL
Intervention: NCES suspended in PRP
Number of subjects: 21
Study 30506679 — intervention group
Group type: COMPARATOR
Intervention: NCES suspended in PBS
Number of subjects: 21
Study 27835048 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg OD + nifedipine
Number of subjects: 108
Study 27835048 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 108
Study 25707379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (designed to achieve and maintain >7% weight loss through increased physical activity and reduced caloric intake)
Number of subjects: 1019
Study 25707379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1019
Study 25707379 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (received social support and diabetes education)
Number of subjects: 1019
Study 24641486 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants instructed to be consistent in the form of their gestures and to teach them to the experimenter.
Number of subjects: 0
Study 24641486 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants describing reversible events in pantomime.
Number of subjects: 0
Study 24641486 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants describing non-reversible events in pantomime.
Number of subjects: 0
Study 22612061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam‐ampicillin
Number of subjects: 191
Study 22612061 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 191
Study 22612061 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose prophylaxis
Number of subjects: 191
Study 22612061 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dose 12 hours after prophylaxis
Number of subjects: 191
Study 22612061 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose until nephrostomy tube removal
Number of subjects: 191
Study 20020612 — intervention group
Group type: EXPERIMENTAL
Intervention: Imunofan
Number of subjects: 0
Study 20020612 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 17317221 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent stimulation of the rubber hand and the subject's hand with slight differences in posture.
Number of subjects: 0
Study 17317221 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent stimulation in hand‐centred space but congruent in external space.
Number of subjects: 0
Study 17317221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch between stimulation delivered to the subject's hand and the rubber hand.
Number of subjects: 0
Study 17317221 — intervention group
Group type: EXPERIMENTAL
Intervention: Small changes in the subject's hand posture.
Number of subjects: 0
Study 17317221 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture transformations applied to the rubber hand.
Number of subjects: 0
Study 15347709 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF gene therapy (naked plasmid DNA encoding for human VEGF165)
Number of subjects: 35
Study 15347709 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy (direct myocardial revascularization)
Number of subjects: 35
Study 15347709 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control)
Number of subjects: 35
Study 11464069 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 11464069 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12
Study 11464069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9504354 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (2 mg daily)
Number of subjects: 21
Study 9504354 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg daily)
Number of subjects: 21
Study 7519554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-opioid mixture through a lumbar epidural catheter
Number of subjects: 19
Study 7519554 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous opioid
Number of subjects: 19
Study 3354411 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 25
Study 3354411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 25
Study 3354411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Lorcainide
Number of subjects: 25
Study 3354411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Lorcainide
Number of subjects: 25
Study 3354411 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 25
Study 4335443 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (16,000 IU single oral dose)
Number of subjects: 26
Study 4335443 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (2,640 IU/day for 2 months)
Number of subjects: 26
Study 4335443 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxycholecalciferol (6,000 to 30,000 IU/day for 6 months to 2 years)
Number of subjects: 26
Study 4335443 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxycholecalciferol (2,640 IU/day)
Number of subjects: 26
Study 4335443 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxycholecalciferol (varied doses)
Number of subjects: 26
Study 31116286 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomeric separators
Number of subjects: 108
Study 31116286 — intervention group
Group type: EXPERIMENTAL
Intervention: Kesling separators
Number of subjects: 108
Study 31116286 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansal separators
Number of subjects: 108
Study 27488859 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel for 6 weeks at loading/maintenance doses of 20/3.75 mg (Continued Group; n = 68)
Number of subjects: 136
Study 27488859 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group; n = 68)
Number of subjects: 136
Study 27488859 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel for 6 weeks (Continued Group)
Number of subjects: 136
Study 27488859 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group)
Number of subjects: 136
Study 27488859 — intervention group
Group type: COMPARATOR
Intervention: Switched Group (CYP2C19 gene polymorphisms)
Number of subjects: 136
Study 25875843 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 injections of HIV‐DNA, 1000 μg total dose (3 Env and 2 Gag encoding plasmids)
Number of subjects: 129
Study 25875843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 injections of combined HIV‐DNA pools, 600 μg total dose
Number of subjects: 129
Study 25875843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 injections with separated pools of HIV‐DNA, 600 μg total dose
Number of subjects: 129
Study 23557223 — intervention group
Group type: COMPARATOR
Intervention: C-Loop haptic design without CTR
Number of subjects: 135
Study 23557223 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Loop haptic design with CTR
Number of subjects: 135
Study 23557223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate-haptic design
Number of subjects: 135